Member Info for Mafuta

Now I'll keep this short for those with the attention span of a goldfish ... It's no surprise that the MMs want your shares they have been at it for the last few months, nothing new there .. they've been manipulating the price over a long period of time helped out by low volumes ... The only thing that will change that is news and that is due anytime ... Also don't confuse PH and its trading arm they are separate entities and the legalities are very clear regarding collusion ... The BOD have hidden nothing regarding the consolidation and today we know the proposed ratio if you can be bothered visit the company website or the RNS and read all about it. . Do some simple maths on the current share price and you will see after consolidation we will be in NASDAQ territory ... Just sit on your hands or get out of the kitchen if it's too hot for you ... I repeat: I know what I would be doing if I had spare funds ... Pesky tax year

The MMs want your shares ... They will manipulate the market to scare you into selling ... It is simple as that ... they likely have a a large book to close and they know news will drop soon ... Just sit on your hands ... And if you can't stand the heat get out of the kitchen ...

We have now got one post wonders talking about Theranos ... Give me strength

Great news ... the fact that our Chinese partners will carry the costs of further R&D ia a major plus

And I would add ... today's levels are a very attractive level to get in at or to average down as and when required ... DYOR etc. ... I know what I would be doing if I had spare funds ...

https://investor.sierraoncology.com/news-releases/news-details/2022/Sierra-Oncology-Announces-Closing-of-Upsized-Public-Offering-of-135.0-Million-of-Securities/default.aspx

Laz ... I expect an RNS on toxicity results as this has a direct bearing on how we progress 1801 to the next pivotal stage ... what I do not expect is any great depth of detail ... most likely something along the lines of: " the toxicity study has yielded excellent results as predicted and this will allow us to progress to the next stage ..." ... watch this space and sit on those hands.

31 January, 2022 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company') a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies' ('AnaBio') microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform.

Interesting to note that Sierra issued 11 form 4's yesterday (Same as our TR1's)

SOG ... Spot on the problem the brokers have is that the majority of shares are in the hands of PI ... Hence the pump and dump tactics ... The client will want closure soon so remain sitting on your hands ... And don't get your knickers in a knot over an admin error which is not the first time ... Perhaps the bod need to think about changing their legal advisors ... Don't panic Mr Mainwaring

Spanky ... you are right MCap is the important indicator ... not that Sierra are in a position to spend ... they are cash strapped at the moment

Warty ... the problem is the lack of volume and this allows the MMs to play ... we won't likely get much volume until decent news drops ... till then it's a waiting game

I think there may be a bit more to the change in reporting from £ to $ ... Preparation for NASDAQ listing?

. Total revenue of £14.4m (£15.3m at constant currency), 13% increase on prior year (20% at constant currency)

· Cash position of £5.7m at year end, supports current business growth plan

· Particularly strong growth in BioRinse®, 24% increase on prior year (34% at constant currency) aided by the completion of Phase 1 of expansion project in the year

· Presentational currency in annual accounts to change to USD, from GBP

Expect a re-rate soon

Our portfolio also includes SRA737, a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), an emerging target for the treatment of cancer which has a key role in the DNA Damage Response (DDR). In November 2020, we entered into an amendment to the License Agreement with CRT SPioneer Fund (CPF) to allow for the potential future clinical development of SRA737. We continue to evaluate several options for combination studies with momelotinib, SRA515 and SRA737 and hope to initiate one or more of them in 2022.
737 is off the back burner and we're cooking on gas ...

Yep they need funds to progress ... Guess what? 737 and it's not a Boeing either

https://investor.sierraoncology.com/news-releases/news-details/2022/Sierra-Oncology-Announces-Momelotinib-Achieved-Statistically-Significant-Benefit-on-Symptoms-Anemia-and-Splenic-Size-in-the-Pivotal-MOMENTUM-Study-for-Myelofibrosis/default.aspx

https://www.edisongroup.com/edison-open-house-global-healthcare-2022/

A vote of confidence

https://www.lse.co.uk/news/NUM/press-thg-hands-watchdog-dossier-alleging-share-price-fall-collusion-jfxdpevtap35bhx.html
They had better behave themselves